Showing results (641-650 of 658) with videos related to

Sort By:
Pageof 66
Cell|September 28, 2000
Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2)P Revy, T Muto, Y Levy, et al.
The New England Journal of Medicine|October 19, 2018
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesDominic Keating, Gautham Marigowda, Lucy Burr, et al.
International Journal of Environmental Research and Public Health|April 13, 2023
Cell Phone Radiation Exposure Limits and Engineering SolutionsPaul Héroux, Igor Belyaev, Kent Chamberlin, et al.
Blood|July 27, 2018
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AMLAmir T Fathi, Harry P Erba, Jeffrey E Lancet, et al.
Nature Medicine|October 2, 2023
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trialNizar J Bahlis, Caitlin L Costello, Noopur S Raje, et al.
The New England Journal of Medicine|November 8, 2019
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del AllelePeter G Middleton, Marcus A Mall, Pavel Dřevínek, et al.
The New England Journal of Medicine|October 19, 2018
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesJane C Davies, Samuel M Moskowitz, Cynthia Brown, et al.
Lancet (London, England)|November 5, 2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialHarry G M Heijerman, Edward F McKone, Damian G Downey, et al.
Annals of the Rheumatic Diseases|January 22, 2009
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamideF A Houssiau, C Vasconcelos, D D'Cruz, et al.
The New England Journal of Medicine|August 26, 2021
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function GenotypesPeter J Barry, Marcus A Mall, Antonio Álvarez, et al.
Pageof 66